DA Davidson cuts Phreesia stock price target on revenue assumptions

DA Davidson cut its Phreesia (PHR) price target to $13.00 from $14.00 while keeping a Buy rating, pushing out the AccessOne growth ramp to FY2028 and moderating subscription revenue assumptions. In reported Q2 FY2027 results, adjusted EBITDA rose to $32.9M (vs. $30.7M consensus) and revenue edged up to $129.5M (vs. $129.1M), but adjusted EPS missed at $0.03 vs. $0.09. Net tone is mixed: stronger network solutions momentum supports the Buy call, but the earnings/guidance reception and revised ramp drive the lower target.

Analysis

The cut to out-year assumptions matters more than the maintained Buy: it signals the market is still being asked to pay for a monetization story that has slipped further into the future. For a sub-scale healthcare software name, that usually means the stock can hold on EBITDA progress but loses the right to a growth multiple until management proves the delayed initiative is actually converting, not just being discussed.

The offset is that higher network contribution is the better-quality revenue mix: more transactional, less dependent on long subscription ramps, and potentially a cleaner path to margin leverage. If that mix shift holds, PHR can still compound cash flow even with slower top-line acceleration. If it does not, adjacent payment and revenue-cycle platforms with more embedded distribution — especially WAY and larger incumbent healthcare IT vendors — can take share while hospitals continue to push for lower-cost patient payment options.

Near term, the stock is likely driven by whether management can quantify upside in network activity rather than by the latest in-line quarter. Over 1-3 months, the catalyst is a better read on bookings/usage; over 6-18 months, it is whether AccessOne becomes a meaningful revenue bridge or just a deferred optionality item. The contrarian risk is that the market may be over-discounting near-term execution while underestimating margin inflection, but a second delay in the growth ramp would likely cap upside and keep the multiple in low-teens EBITDA territory.

Key Decisions for Investors

• Neutral to slightly underweight PHR here; do not add aggressively until the next print confirms network-solution acceleration or a tighter AccessOne conversion timeline. If the stock rallies back toward $11.50-$12.00 without better forward commentary, use strength to trim.
• Pair trade: long WAY / short PHR over 1-3 months. Thesis: WAY has cleaner near-term monetization of payment-flow growth, while PHR’s delayed ramp leaves less room for multiple expansion. Risk/reward is favorable if healthcare payments remain a secular winner and PHR execution stays mixed.
• If already long PHR, consider selling upside via covered calls into any post-earnings bounce; implied upside looks limited until management shows that subscription deceleration is stabilizing. Falsify this by a quarter of clear ARR re-acceleration or an upward FY guide.
• Set an alert on two metrics: network solutions contribution growth and any explicit AccessOne milestone update. Without both, this is a hold-not-a-buy story.